Decision made on plans to convert baby clothing shop after smell complaints
Glasgow City Council planners have thrown out an application to change the use of the old Babitique store on Dumbarton Road.
Three neighbours objected to Akhtar Ali's proposal, raising concerns over smells, increased noise and the possibility of the venue attracting drunk people late at night.
Planners decided the project would result in 'increased noise, activity and cooking fumes to the detriment' of residents in the tenement above. They also ruled it would 'erode the retail character' of the area.
The applicant wanted to convert the unit into a new branch of the Chicken Cottage franchise, which would have opened from 11.30am to 10pm from Monday to Saturday. The plan was to close at 9pm on Sundays.
But one neighbour said: 'There is already a fast food takeaway place two doors down with an extractor fan in the same back court, which generates a lot of noise and smell from the food they are producing.
'To add another takeaway and flue to the same back court would add more noise disruption and smell.'
READ MORE: New pictures show how George Square's £20m makeover will change City Chambers
Another resident added an extraction flue would be 'directly below the windows at the back of my flat' and they were 'very concerned' about the smell as well as 'potential obstruction' of their windows.
They also said there was a risk the takeaway would attract vermin and added: 'I am very opposed to a restaurant/takeaway being opened directly below my residence due to the fact that there… a high potential that it will attract drunk people in the night.
'My bedroom is at the front of the building and as such, this would be an extreme disturbance for me.'
A council official said the proposal would result in the 'loss of a retail unit to the detriment of the vitality and viability of the town centre'.
The shop is 'not listed as a long-term vacant unit and no marketing information has been provided to demonstrate a long-term lack of retail interest in the unit', they added.
Their report also said a 'hot food takeaway could result in disruption to nearby residential amenity by the nature of the increased opening hours and the increased noise and activity'.
The council's decision also said no information on the proposed maintenance scheduled for the ventilation system had been provided, and the plan did not include the required bike parking for staff.
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Skift
3 hours ago
- Skift
MakeMyTrip Expands International Listings with Premier Inn's 900+ European Hotels
As direct competition in India is increasing and suppliers are cutting middlemen, MakeMyTrip is moving to international markets to increase supply and distinguish itself. Online travel agency MakeMyTrip has partnered with UK-based hotel chain Premier Inn. Under the partnership, more than 900 Premier Inn properties across the UK, Germany and Ireland have been added to MakeMyTrip's international hotel portfolio. For Premier Inn, the partnership with MakeMyTrip will help increase awareness of the brand in India and neighboring countries. MakeMyTrip's decision was driven by the UK being one of the most preferred destinations for Indian travelers, said Rajesh Magow, co-founder and group CEO of MakeMyTrip. The partnership is a key part of the OTA's strategy to capitalize on India's outbound surge. International Strategy: This is MakeMyTrip's latest effort to expand its international hotel supply. The company has been using a direct contracting strategy to add more hotels to its portfolio, with a focus on high-demand outbound destinations. In a statement, the company said in the past year, it has added more than 2,000 directly contracted hotels across 50 cities in 20 countries. 'These 50 cities collectively account for more than half of India's outbound travel,' MakeMyTrip's statement read. 'Over the past twelve months, we have pursued a focused strategy to deepen our international accommodation offerings across key hubs, particularly in long haul markets such as the UK, Europe, and the U.S.,' said Magow. �
Yahoo
13 hours ago
- Yahoo
AstraZeneca CFO talks tariffs & shifting focus to US market
AstraZeneca's (AZN) revenue hit a record high in the second quarter, driven by cancer drug sales and growth in the US market. AstraZeneca CFO Aradhana Sarin sits down with Market Catalysts host Julie Hyman and Yahoo Finance Senior Healthcare Reporter Anjalee Khemlani to discuss the company's strategy to focus on the US and the impact of tariffs. To watch more expert insights and analysis on the latest market action, check out more Market Catalysts here. I wonder on the Obviously, the company is celebrating the fact that you hit the largest revenues reported for the quarter. That's really good news, especially as the stated goal is to grow by 2030, and half of that to be part of the US. Talk to me about that and the shift to being a quote-unquote American company now, rather than a sort of UK-based one that we've thought of all these years. Uh, so we, you know, last May, we set this ambition of achieving 80 billion in revenues by 2030, which was almost, you know, doubling our revenues from a 2023 base. Um, and, uh, the US is our our fastest growing market. Uh, when we stack, we don't stack very highly right now, uh, in the US when when you compare pharma revenues because a lot of the pharma companies in the US have much bigger sort of revenue base, but we're growing very fast and our hope is that we'll come, you know, in in in the top five and have half of our revenue. We also set an ambition to have 20 new medicines by 2030. And, um, we already have nine of them and, uh, we announced results for another five of them. So hopefully, uh, that shows that we're on track to to achieve that goal. Well, talk to me about why the US is growing that much far faster. Is it because the dynamics of the healthcare system help boost revenues with more prescribing the the way the PBM system is set up? What are the factors that are helping you grow and are helping you stay confident about achieving that goal? So, there are a bunch of different factors. Um, I think the US is still probably the the best market in the world that rewards innovation. Uh, and we are an innovation-driven company. And so, when new therapies come, you know, we we had a product for breast cancer in her two. Uh, we announced data for another breast cancer product. But as soon as new therapy comes, um, the US market is almost the first to provide access to patients for that new therapy. Uh, secondly, physicians are really, um, you know, we go to Congresses like ASCO where there's, you know, tens of thousands of oncology physicians. They're really into, um, looking at the data and making data-driven decisions. So, again, the, you know, the physicians want the best for their patients and patients are able to get access to medicines very quickly once, you know, drug is approved and so forth in the in the innovative space. In many other markets in the world, that whole process to get approval and then get access and reimbursement just takes a very long time. So that's one reason. Um, the second reason, uh, I think particularly beneficial for oncology medicines, uh, is the part D reform. Uh, so on one hand, the part D reform that was enacted hurts us because we are responsible for paying 20% in the catastrophic phase. But from a patient standpoint, if you're a patient, um, you know, in Medicare, your out of pocket is capped at $2,000. So you can get the best therapy and have no more to pay out of pocket, right? So being in that patient population and getting the best access to medicines and the best care and have your out of pocket limited, uh, is is also great for patients. Um, so I think it's it's where physicians and patients and innovation is rewarded. And that's why it's growing faster given our portfolio is all innovative medicines. So, so let's turn then to the manufacturing base rate and the investment that you're making in the US. And I have to ask about tariffs because we even as we discussed it this morning, this new EU sort of framework agreement, it's still sort of unclear. Are pharmaceuticals coming from the EU exempt? Are they not exempt? It seems a little unclear. So how under what assumption are you operating and how do you operate in that kind of environment? Um, yeah, so you know, I would say this is not a tariff is obviously new, but how we've been thinking about our strategic manufacturing, um, is probably goes back three, four years. So post COVID, we made a strategic decision because we're such a global company that we needed to have segregated supply chains. Um, so for example, uh, in in China and in the emerging markets, we supply a lot of that product from China. Um, in the US, majority of the product is supplied from the US and and so forth in Europe. There is, uh, you know, small minority of product, handful of products actually that we still import from Europe into the US. But we do have excess capacity in the US to manufacture those products. Uh, so what we're, you know, we have 11 manufacturing sites in in the US. So our intention once the tariffs, etc. were were announced and there was talks of tariffs, uh, in the short term was just manage through inventory, so build more inventory in in the US. Um, but we've also started tech transfers for those products which we do import and that those tech transfers would be completed, you know, within a within a year or so, so that we can be fully, you know, not just have the majority, but 100% of it being manufactured in in the US. Um, this new facility that we announced, uh, was part of the plan anyway, but that's a separate has nothing to do with tariffs. It's actually based on the demand that we see potentially for our cardiovascular for new cardiovascular medicine. So, um, but you know, you're right, I think there is a little bit of confusion on when the tariffs are going to be implemented. Um, there is from what I've heard, it is a 15%, but there's also talk that that's the cap. Uh, and, uh, the administration is sort of going to wait for the 232 investigation to actually put them into effect or decide. So, uh, in either case, I think we're very well prepared and and we probably have less exposure than than many companies. Related Videos Market's 'fuel' for further P/E expansion is 'nearing empty' Nvidia's TSMC order, Eli Lilly & Novo Nordisk sink, JPMorgan & Apple card Royal Caribbean, Merck, FuboTV: Trending Tickers Why Spotify stock is sinking double digits on Q2 earnings Sign in to access your portfolio
Yahoo
13 hours ago
- Yahoo
US-Based geniant Expands International Footprint With Acquisition of London-Based Brand Experience Studio NewTerritory
Dallas, Texas & London, United Kingdom--(Newsfile Corp. - July 29, 2025) - Today, leading US-based experience consultancy, geniant, has announced its acquisition of NewTerritory, an award-winning UK-based design and brand experience studio founded by former Head of Design for Virgin Atlantic and LG Europe. The London-based team has gained international recognition through multi-sector, visionary projects for clients that include Delta Air Lines, Mercedes-Benz AG, Airbus and Coca-Cola. This move accelerates geniant's global growth strategy while directly addressing a fundamental need in business transformation - the ability to look across all interconnected customer and employee touchpoints, identify the moments that matter most, and then design and deliver next-generation experiences. "As more companies accept that the quality of their customer and employee experiences are key to marketplace success, the real challenge becomes identifying which moments to optimize first - and understanding why they matter," said David Lancashire, geniant's Chairman & Co-CEO. "NewTerritory's expertise in uncovering and shaping those Signature Moments that leave a lasting impression is a powerful addition to geniant's capabilities, strengthening our ability to guide companies toward what truly drives loyalty and impact." Commenting on the deal announcement, Luke Miles, Founder of NewTerritory, said: "Organizations face growing pressure to create distinctive, memorable experiences but often turn to partners unable to deliver at the intersection of creative vision, strategic insights and AI. What drew us to geniant was not just their mastery of these critical capabilities, but a shared belief that the current approach is broken, and that together we can help reimagine better workflows and experiences and actually bring them to life." geniant helps organizations see the big picture, bringing deep insight into customer needs together with a detailed understanding of internal workflows, through its integrated 'Insights, Experiences and AI-First' approach, delivering next-generation experiences. Insights: Proprietary research and analytics pinpoint critical moments that genuinely matter to customers and employees. Experiences: Elevating these moments into unified journeys across digital products, physical environments, and human interactions. AI-First: Guiding enterprises through IT modernization by embedding AI at the heart of products, workflows, and decision-making. Prove value quickly with targeted "lighthouse" projects that build momentum. Prioritize AI investments in alignment with clear business goals to achieve measurable results. Build an adaptive technology foundation that empowers leaders across the enterprise to launch new offerings, streamline operations, and scale with confidence. This cohesive approach enables brands to break free from the "experience echo chamber" and foster authentic, lasting customer and employee loyalty. -ENDS- For media information and editorial images, please contact: hello@ For high resolution copies of these images, please get in touch with the PR contact above: geniant, Chicago Studio To view an enhanced version of this graphic, please visit: New Territory, London Studio To view an enhanced version of this graphic, please visit: Luke Miles, Founder of NewTerritory To view an enhanced version of this graphic, please visit: About NewTerritory NewTerritory is a brand experience studio with capabilities spanning visioning, experience design, and communication. Based in London, the team, guided by data-driven insight, crafts seamless end-to-end experiences that build advocacy and deliver long-term value for brands. Founded by former head of design at Virgin Atlantic, Luke Miles, the studio is recognized for delivering game-changing brands and products within the travel, hospitality, and infrastructure industries. Visit to find out more. About geniant geniant is an experience consultancy helping organizations transform by uniting insights, customer and employee experiences, and AI-first technology. With a proven track record across diverse industries, geniant partners with enterprises to reimagine every touchpoint to deliver measurable business impact. Visit to learn more. To view the source version of this press release, please visit Sign in to access your portfolio
